GlassScriptPhysician profile
Jagmohan Singh
NPI 1972619013
$2,155.94
in general payments reported to CMS, 2019-2025
21 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $223 · 2022: $141 · 2023: $429 · 2024: $430 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $484.73 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $328.47 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $321.73 | 2023-2025 | Vraylar, Ubrelvy |
| Allergan, INC. | $98.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.18 | 2019-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $94.96 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $94.18 | 2019-2020 | |
| Amgen INC. | $89.78 | 2019-2025 | Otezla, Repatha |
| Lilly USA, LLC | $85.65 | 2019-2024 | Mounjaro |
| Exact Sciences Corporation | $84.26 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $62.51 | 2020-2024 | |
| Glaxosmithkline, LLC. | $58.64 | 2020-2025 | Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $54.95 | 2019-2024 | Xarelto |
| Corcept Therapeutics | $42.80 | 2023 | Korlym |
| Astellas Pharma US INC | $36.89 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $31.66 | 2019-2024 | Eliquis |
| Amarin Pharma, INC. | $19.30 | 2020 | |
| Lundbeck LLC | $18.53 | 2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.00 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $17.41 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $15.89 | 2023 | Verquvo, Belsomra, Steglatro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagmohan Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.